Clinician Letters

2021

  • COVID-19 Update for Virginia – September 30
    • CDC Recommends a Booster Dose of Pfizer-BioNTech Vaccine Following a Primary Series for Certain Populations
    • COVID-19 Vaccination and Pregnancy
    • Vaccination for Children Aged 5 to 11 Years
    • Update on Monoclonal Antibody Treatment for COVID-19 Distribution
  • COVID-19 Updates for Virginia – September 20
    • Back-to-School Resources and Reminders
    • CDC’s Health Alert Network (HAN) Health Advisory about Ivermectin
    • Update on Monoclonal Antibody Treatment for COVID-19
    • Virginia Immunization Information System Requires All Immunizations January 2022
  • Update on Measles in Virginia – September 14
  • COVID-19 Update for Virginia – August 26
    • FDA Grants Full Approval to Pfizer-BioNTech COVID-19 Vaccine
    • Booster Dose of mRNA Vaccine for General Adult Population to Start in Mid-September
    • Coadministration of COVID-19 and Influenza Vaccines
    • Additional Updates about Respiratory Syncytial Virus
  • COVID-19 Update for Virginia – August 16
    • CDC Recommends an Additional Dose of mRNA Vaccine Following a Primary Series in Certain Immunocompromised People
    • CDC Strengthens Vaccine Recommendation for People Who Are Pregnant, Breastfeeding, or Thinking of Becoming Pregnant
    • VDH Reminds Clinicians of Testing and Masking Recommendations
  • Health Commissioner Update – August 6
    • Updates on the Delta (B.1.617.2) Variant and Guidance
    • Monoclonal Antibody Therapy and Postexposure Prophylaxis
    • Guillain-Barré syndrome after receiving Johnson & Johnson’s COVID-19 vaccine
    • Updates about Non-COVID-19 Respiratory Viruses
    • Burkholderia cepacia complex Infections Associated with Contaminated Ultrasound Gel
    • Back-to-school Vaccinations and Updated Resources
  • COVID-19 Update for Virginia – June 30
    • Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination
    • Monoclonal Antibody Update
    • Updates on the Delta (B.1.617.2) and the Epsilon (B.1.427/B.1.429) Variants
    • New CDC Viral Testing Tool
    • Preparing for Heat-Related Illness
  • COVID-19 Update for Virginia – May 14
    • Updated CDC Guidance for Fully Vaccinated People
    • Pfizer-BioNTech COVID-19 Authorized and Recommended for 12-15 Year Olds
    • Importance of Not Missing COVID-19 Vaccination Opportunities
    • Importance of Second Dose Administration of Pfizer-BioNTech and Moderna Vaccines
    • Upcoming Webinar with a Pediatric COVID-19 Vaccination Expert Panel
    • Importance of Testing Returning International Travelers and Encouraging Quarantine
  • Candida auris Cases are on the Rise in Virginia – May 7
  • COVID-19 Update for Virginia – April 7
    • Importance of Diagnostic and Screening COVID-19 Testing in Virginia
    • SARS-CoV-2 Variants
    • Importance of Reporting COVID-19 Outbreaks
    • Cases of Vaccine Breakthrough
  • COVID-19 Update for Virginia – March 4
    • Johnson & Johnson’s Janssen COVID-19 Vaccine
    • Patient Outreach about COVID-19 Vaccination
    • COVID-19 Vaccination Clinic Best Practices
    • Updated Quarantine Recommendations for Fully Vaccinated People
    • Work Restrictions for Exposed Healthcare Personnel
    • Multisystem Inflammatory Syndrome in Children (MIS-C)
    • SARS-CoV-2 Variants in Virginia
    • Ebola Virus Disease Outbreaks in the Democratic Republic of Congo and Guinea
  • COVID-19 Update for Virginia – January 25
    • Required Information for COVID-19 Immunizations
    • COVID-19 Vaccine Allocation Methodology
    • B.1.1.7 Variant of COVID-19 Virus Detected in Virginia
    • Travel Restrictions for People Entering the United States
    • New Text Messaging Service to Streamline Positive Test Result Awareness and Exposure Notifications
  • COVID-19 Update for Virginia – January 11
    • Updates on COVID-19 Vaccine Prioritization for Phases 1b and 1c
    • Submit your intent today to administer COVID-19 vaccine
    • Enroll today to become a vaccination provider in Virginia’s Medical Reserve Corps
    • FDA Communication: Genetic Variants of SARS-CoV-2 May Lead to False Negative Results with Molecular Tests for Detection of SARS-CoV-2
    • FDA Safety Communication: Risk of False Results with the Curative SARS-CoV-2 Test for COVID-19

2020

2019

2018

  • Disease Regulations Update – November 16 **VDH would like to offer clarification to the November 16th, 2018 clinician letter. In that letter, it identified that “the requirement that physicians and directors of medical facilities report influenza by number of cases (report total number per week and by type of influenza, if known) has been removed from the regulations”. This statement was not accurate.  The only change regarding influenza reporting is that the list of conditions that shall be reported was modified to “Influenza, Confirmed”. 
  • Acute Flaccid Myelitis – November 8